NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the…
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal …
Source: Eagletribune
Read Full Story →
